CTIS2024-511996-13-00招募中1 期
An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma - IOB-013/KN-D18
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 407
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer 8th edition guidelines not amenable to local therapy (90). 2. Patients are treatment naive—that is, no previous systemic anticancer therapy for unresectable or metastatic melanoma. For clarification, the following patients are eligible: a. Patients with BRAFV600 mutation-positive melanoma are eligible if treatment naive and without rapidly progressive disease as per investigators assessment.D ocumented BRAFV600 mutation status must be available from all patients prior to trial entry. b. Patients who have received previous adjuvant and/or neoadjuvant therapy with targeted therapy or immune therapy are eligible if administered the last dose at least 6 months before inclusion and if relapse did not occur during active treatment or within 6 months of treatment discontinuation. 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0 or 1 assessed within 10 days before randomization. 4. Life expectancy of >24 weeks at the time of informed consent per investigator assessment. 5. At least 1 measurable lesion according to response evaluation criteria for solid tumors (RECIST v1.1) and confirmed by IRC. Note: Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions before inclusion. 6. Provision of archival (obtained within 3 months) or newly acquired biopsy tissue not previously irradiated, and blood at screening for biomarker assessments. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. Note: • Use of archival tissue >3 months old, may be considered after communication with and agreement by the Sponsor. • If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut (details pertaining to tumor tissue submission can be found in the Lab Manual). For the full list of inclusion criteria, please refer to the protocol.
排除标准
- •1. Uveal/ocular, acral or mucosal melanoma 2. Patients with known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease are excluded with the following exception: ? Patients with controlled (stable) brain metastases will be allowed to enroll (subject to baseline magnetic resonance imaging confirmation). Controlled (stable) brain metastases are defined as those with no radiographic progression for at least 4 weeks after radiation and/or surgical treatment at the time of signed informed consent. Patients must have been off steroids for at least 2 weeks before signed informed consent and have no new or progressive neurological signs and symptoms. 3. Patient has received previous radiotherapy within 2 weeks of start of trial treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease. 4. Patients with BRAFV600-positive disease who are experiencing rapidly progressing disease and/or have received standard first-line therapy with BRAF and/or MEK inhibitor for unresectable or metastatic disease. 5. Active known or suspected autoimmune disease that has required systemic treatment in the past 2 years. Patients with type I diabetes mellitus; hypothyroidism only requiring hormone replacement; skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; or conditions not expected to recur in the absence of an external trigger are permitted to enroll. 6. Presence of other primary malignancies, with the exception of non-melanoma skin cancer, carcinoma in situ or stage I nonulcerative melanoma, in situ cervical cancer, in situ breast cancer and prostate cancer for patients who are receiving androgen deprivation therapy only. Other primary malignancies are only acceptable if there is no ongoing active disease and no biomarker indication of active disease. 7. Active infection requiring systemic therapy 8. History of active tuberculosis For the full list of exclusion criteria, please refer to the protocol.
研究者
相似试验
进行中（未招募）
1 期
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013/KN-D18)EUCTR2021-004594-32-PLIO Biotech ApS380
进行中（未招募）
1 期
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013/KN-D18)Patients with previously untreated, unresectable or metastatic (advanced) melanomaMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004594-32-DKIO Biotech ApS380
进行中（未招募）
1 期
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013/KN-D18)EUCTR2021-004594-32-ESIO Biotech ApS300
进行中（未招募）
1 期
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013/KN-D18)Patients with previously untreated, unresectable or metastatic (advanced) melanomaMedDRA version: 27.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004594-32-DEIO Biotech ApS380
进行中（未招募）
1 期
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013/KN-D18)EUCTR2021-004594-32-CZIO Biotech ApS380